Affinity Asset Advisors LLC Makes New $2.26 Million Investment in Monopar Therapeutics Inc. $MNPR

Key Points

• Affinity Asset Advisors LLC acquired 62,000 shares of Monopar Therapeutics, representing approximately $2.26 million, which gives them a 1.01% stake in the company.
• Recent insider sales included transactions by Director Christopher M. Starr and CEO Chandler Robinson, both selling 16,800 shares at $40.00 each, significantly reducing their ownership in the company.
• Brokerage firms have set aggressive price targets for Monopar Therapeutics, with estimates ranging from $60.00 to $74.00, indicating strong buy recommendations from multiple analysts.

Affinity Asset Advisors LLC bought a new position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 62,000 shares of the company's stock, valued at approximately $2,257,000. Affinity Asset Advisors LLC owned approximately 1.01% of Monopar Therapeutics as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of MNPR. Janus Henderson Group PLC acquired a new position in Monopar Therapeutics during the fourth quarter worth $23,435,000. Adage Capital Partners GP L.L.C. acquired a new stake in Monopar Therapeutics during the fourth quarter worth about $13,182,000. RA Capital Management L.P. acquired a new stake in Monopar Therapeutics during the fourth quarter worth about $11,247,000. Point72 Asset Management L.P. acquired a new stake in Monopar Therapeutics during the fourth quarter worth about $3,694,000. Finally, Geode Capital Management LLC increased its stake in Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after acquiring an additional 24,530 shares during the last quarter. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MNPR has been the subject of a number of recent analyst reports. Chardan Capital restated a "buy" rating and set a $60.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. Wall Street Zen upgraded Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald restated an "overweight" rating and set a $74.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday. Finally, HC Wainwright began coverage on Monopar Therapeutics in a report on Tuesday. They set a "buy" rating and a $70.00 target price on the stock. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $66.00.

Insider Buying and Selling

In other news, Director Christopher M. Starr sold 16,800 shares of the firm's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the director owned 5,173 shares of the company's stock, valued at $206,920. This trade represents a 76.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the firm's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $356,160.00. Following the completion of the sale, the director directly owned 11,486 shares of the company's stock, valued at approximately $459,440. This trade represents a 43.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,504 shares of company stock worth $1,700,160 in the last three months. 20.50% of the stock is currently owned by insiders.

Monopar Therapeutics Trading Down 5.3%

Shares of NASDAQ MNPR traded down $1.91 during mid-day trading on Friday, hitting $34.15. The company had a trading volume of 15,130 shares, compared to its average volume of 34,835. Monopar Therapeutics Inc. has a 12 month low of $2.25 and a 12 month high of $54.30. The firm's 50 day simple moving average is $37.87 and its two-hundred day simple moving average is $37.04.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.12. Equities research analysts expect that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.